The study revealed the popular weight loss drug semaglutide — commonly known as Ozempic and Wegovy — is highly effective at treating heart failure in patients with obesity.
A groundbreaking study, led by Mikhail Kosiborod, MD, vice president of research at Saint Luke's Health System, has been named the scientific breakthrough of the year by Science Magazine.
Mental health can play a big role in setting yourself up for success when it comes to setting New Year’s resolutions and making healthy lifestyle changes.
Dr. Kosiborod presented the main results of STEP-HFpEF trial during the opening late breaking clinical trial session at the European Society of Cardiology Congress (ESC Congress)—the world’s largest cardiology conference.
U.S. News & World Report has named Saint Luke’s East Hospital as a 2024 High Performing hospital for Maternity Care (Uncomplicated Pregnancy). This is the highest award a hospital can earn for “U.S. News’” Best Hospitals for Maternity Care.
Presented by the lead author Mikhail Kosiborod, MD, the STEP-HFpEF trial is recognized by Science Magazine as Breakthrough of the Year throughout all science.
As the holidays are here, so is the uptick in heart attacks. With the season's stress, many people may ignore warning signs and put off getting care. But one Kansas City Santa recognized his signs early and got help in the nick of time.
According to the American Heart Association, more people die from heart attacks on December 25 than any other day of the year, with December 26 and New Year’s Day following close behind.
